Commentary on “Liver function effects of SGLT2 inhibitor and GLP ‐1 receptor agonist combination treatment in patients with type 2 diabetes ( post hoc analysis of RECAP study)”

Documenti analoghi

• A decade of SGLT2 inhibitors: Lessons learned and the road ahead in type 2 diabetes
  di: Tomohiko Kimura, et al.
  Pubblicazione: (2025)
• Association of glucagon‐like peptide‐1 receptor agonist use with clinical outcomes in patients with rheumatoid arthritis and type 2 diabetes
  di: Yu‐Ting Yu, et al.
  Pubblicazione: (2026)
• Effect of SGLT‐2 inhibitors on COPD exacerbations in individuals with type 2 diabetes: A meta‐analysis and Bayesian sensitivity analysis
  di: Muhammed Shabil, et al.
  Pubblicazione: (2025)
• The importance of treatment sequencing with SGLT2 inhibitors and GLP ‐1 receptor agonists combination for kidney function preservation in type 2 diabetes
  di: Mario Luca Morieri, et al.
  Pubblicazione: (2026)
• Revisiting the thrifty substrate hypothesis: Ketone bodies as cardioprotective fuels in diabetes and SGLT2 inhibitor therapy
  di: Yoriyasu Suzuki, et al.
  Pubblicazione: (2025)